Scholar Rock Holding Corp (SRRK): Capital Expenditures
$602.0K
Year ended 2025-12-31
$185.0K
Trailing 12 months to 2026-06-30
-17.3%
3-year compound annual growth
-31.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $602.0K | +514.3% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $98.0K | +38.0% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $71.0K | -93.3% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $1.06M | -79.7% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $5.25M | +28.4% | 2023-03-07, From 2021-01-01 |
| 2020-12-31 | $4.09M | +31.2% | 2022-03-07, From 2020-01-01 |
| 2019-12-31 | $3.12M | +108.8% | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | $1.49M | +313.3% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $361.0K | n/a | 2019-03-19, From 2017-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $602.0K | +514.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $145.0K | -73.8% |
| Amgen Inc (AMGN) | 2025-12-31 | $1.86B | +69.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $23.52M | -8.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $564.0K | +45.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $28.85M | -7.0% |
| Biogen Inc. (BIIB) | 2025-12-31 | $153.80M | +0.1% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $522.0K | -7.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $563.00M | +7.6% |
Compare SRRK, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗